Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 12:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vaccine-primed T-cells Clear all
Withdrawn Phase 1 Interventional

Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer

NCT01219907
View directory record Official record
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Stage IV Breast Cancer
Interventions
HER-2/neu peptide vaccine, cyclophosphamide, ex vivo-expanded HER2-specific T cells, laboratory biomarker analysis, flow cytometry, immunoenzyme technique
Biological · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Sep 23, 2026, 12:03 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer

NCT01417000
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
GVAX Pancreas, CRS-207, Cyclophosphamide
Biological · Drug
Lead sponsor
Aduro Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
10
States / cities
Tampa, Florida • Baltimore, Maryland • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Sep 23, 2026, 12:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults

NCT04776317
View directory record Official record
Conditions
COVID-19
Interventions
ChAdV68-S, ChAdV68-S-TCE, SAM-LNP-S, SAM-LNP-S-TCE, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Decatur, Georgia • St Louis, Missouri • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 23, 2026, 12:03 PM EDT
Active, not recruiting Phase 3 Interventional

S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

NCT03091660
View directory record Official record
Conditions
Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
Interventions
BCG Solution, BCG Tokyo-172 Strain Solution, BCG Tokyo-172 Strain Vaccine, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
174
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 23, 2026, 12:03 PM EDT
Completed Phase 1 Interventional

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

NCT03532217
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer
Interventions
PROSTVAC-V, PROSTVAC-F, Nivolumab, Ipilimumab, Neoantigen DNA vaccine, TriGrid Delivery System, Tumor biopsy, Peripheral blood, Fecal samples, Leukapheresis
Biological · Drug · Device + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Sep 23, 2026, 12:03 PM EDT
Withdrawn Phase 1 Interventional

A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT02277392
View directory record Official record
Conditions
Ovarian, Fallopian Tube and Peritoneal Cancer
Interventions
Vaccine---primed, CD3/CD28---costimulated autologous peripheral blood T---cells, SB---485232 (Human recombinant Interleukin---18)
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Sep 23, 2026, 12:03 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults

NCT07183709
View directory record Official record
Conditions
COVID-19
Interventions
PepGNP-COVID19, Sterile Water for Injection
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 23, 2026, 12:03 PM EDT
Terminated Phase 1 Interventional

Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

NCT03422094
View directory record Official record
Conditions
Glioblastoma
Interventions
NeoVax, Nivolumab, Ipilimumab, Research blood draw, Leukapheresis for research
Biological · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Sep 23, 2026, 12:03 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA

NCT04732468
View directory record Official record
Conditions
Covid19
Interventions
hAd5-S-Fusion+N-ETSD (Suspension for injection), hAd5-SFusion+ N-ETSD (Oral capsule)
Biological · Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
El Segundo, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 23, 2026, 12:03 PM EDT
Completed Phase 2 Interventional Results available

Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma

NCT01245673
View directory record Official record
Conditions
Myeloma
Interventions
Prevnar- Pneumococcal Conjugate Vaccine (PCV), Activated/costimulated autologous T-cell, Revlamid® (Lenalidomide), MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC)
Biological · Other · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2020 · Synced Sep 23, 2026, 12:03 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)

NCT04930055
View directory record Official record
Conditions
Cancer
Interventions
COVID-19 Vaccination
Biological
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
2,206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Sep 23, 2026, 12:03 PM EDT
Terminated Phase 1 Interventional

Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer

NCT01312376
View directory record Official record
Conditions
Ovarian Carcinoma, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
OC-DC vaccine, Bevacizumab, cyclophosphamide 300 mg/m2/d for 3 days, fludarabine 30 mg/m2/d for 3 days, ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells
Biological · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 23, 2026, 12:03 PM EDT
Completed Phase 2 Interventional Results available

Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer

NCT00847171
View directory record Official record
Conditions
Breast Cancer
Interventions
allogeneic GM-CSF-secreting breast cancer vaccine, trastuzumab, cyclophosphamide, flow cytometry, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy
Biological · Drug · Other + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Sep 23, 2026, 12:03 PM EDT
Recruiting Phase 1 Interventional

Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma

NCT06514898
View directory record Official record
Conditions
Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma
Interventions
TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Td vaccine, autologous HSCs, Pembrolizumab
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
4 Years to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 23, 2026, 12:03 PM EDT
Completed Phase 1 Interventional Results available

Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3M4 in Persons With HIV-1 Suppressed on ART

NCT05604209
View directory record Official record
Conditions
HIV Vaccine, HIV-1-infection
Interventions
ChAdOx1.HIVconsv62, ChAdOx1.tHIVconsv1, MVA.tHIVconsv4, MVA.tHIVconsv3, Placebo
Biological · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Sep 23, 2026, 12:03 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Functional Consequences of T-bet Expression in Flu-specific Memory B Cells After Live Attenuated Influenza Vaccine (LAIV)

NCT04080245
View directory record Official record
Conditions
Influenza, Human
Interventions
Treatment Group Live Attenuated Flu Vaccine (LAIV)
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Sep 23, 2026, 12:03 PM EDT
Completed Phase 2 Interventional Results available

Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant

NCT01426828
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CD3/CD28
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Sep 23, 2026, 12:03 PM EDT
Completed Phase 1Phase 2 Interventional

Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma

NCT00499577
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
CMV pp65 peptide, hTERT I540/R572Y/D988Y multipeptide vaccine, pneumococcal polyvalent vaccine, survivin Sur1M2 peptide vaccine
Biological
Lead sponsor
University of Maryland Greenebaum Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Sep 23, 2026, 12:03 PM EDT
Recruiting Phase 1 Interventional

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

NCT07374029
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
Interventions
DC/AML Fusion Vaccine, T-Cell Therapy, Decitabine, Venetoclax, GM-CSF
Biological · Drug
Lead sponsor
David Avigan
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 23, 2026, 12:03 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury)

NCT03349983
View directory record Official record
Conditions
Safety Issues
Interventions
MVA-BN-Brachyury/ FPV-Brachyury
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Sep 23, 2026, 12:03 PM EDT
Recruiting Phase 1 Interventional

ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients

NCT06254326
View directory record Official record
Conditions
Recurrent Oligodendroglioma, Progressive Oligodendroglioma
Interventions
TTRNA-DC vaccines with GM-CSF, Autologous Hematopoietic Stem cells (HSCs), TTRNA-xALT, Td vaccine
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 23, 2026, 12:03 PM EDT
Recruiting Phase 1 Interventional

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

NCT06564623
View directory record Official record
Conditions
Biliary Tract Cancers
Interventions
mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)], Durvalumab, Tremelimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 23, 2026, 12:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccine Therapy in Treating Patients With Stage IV Breast Cancer

NCT00791037
View directory record Official record
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
HER-2/neu peptide vaccine, leukapheresis, ex vivo-expanded HER2-specific T cells, cyclophosphamide, sargramostim, laboratory biomarker analysis
Biological · Procedure · Drug + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Sep 23, 2026, 12:03 PM EDT
Not yet recruiting Phase 2 Interventional

Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

NCT07634094
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Paclitaxel, Cisplatin, Bioferon, Rintatolimod, αDC1 Vaccine, Pembrolizumab, Celecoxib, Debulking Procedure
Drug · Biological · Procedure
Lead sponsor
Kalinski, Pawel, MD, PhD
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 23, 2026, 12:03 PM EDT